Scientists at the Institut Pasteur and Inserm have successfully increased the infiltration of immune cells into tumors, thus inducing the immune system to block tumor growth. In an article published in Nature Immunology, the scientists show that, in combination with existing immunotherapies, this process efficiently destroys cancer cells.
Chemokines are small molecules that can attract immune cells towards inflammatory tissues, acting for example during tumor development or upon infection, in order to support migration of lymphocytes into diseased tissues. However, these molecules may be degraded by enzymes, a process that limits the influx of immune cells. For example, the chemokine CXCL10, which induces the recruitment of T lymphocytes into pathological tissues, is rapidly degraded by the enzyme dipeptidylpeptidase 4 (DPP4).
The Dendritic Cell Immunobiology Unit, led by Matthew Albert (Institut Pasteur and Inserm), had previously shown that increased levels of DPP4 and the degraded form of CXCL10 in hepatitis C patients correlate with patients’ inability to respond to interferon treatment. Following these results, the scientists predicted and have now confirmed that inhibiting this enzyme could improve the efficacy of immune responses, in particular antitumor responses.
In a recently published study, Rosa Barreira da Silva, Matthew Albert and their colleagues showed that oral administration of a specific DPP4 inhibitor (sitagliptin) slows the development of several types of cancer in mice. In addition, the authors demonstrated that DPP4 inhibition increased the infiltration of T lymphocytes into tumors, and that the combination of this innovative treatment with existing immunotherapies eradicated the tumor.
DPP4 inhibition blocks tumor growth. Histological section of two mouse melanomas – (a) untreated and (b) treated with sitagliptin, a specific DPP4 inhibitor. Stain: hematoxylin and eosin; scale bar: 500 mm. © Institut Pasteur
Two studies, one theoretical and the other biological and clinical, conducted by Nicolas Foray, radiobiologist at the Combined Research Unit 1052 'Cancer Research Centre of Lyon' (Inserm/CNRS/Centre Léon-Bérard/Lyon I University), have just been published in the International Journal of Radiation Biology and ...
In November 2014, Inserm organised medical follow-up of people who survived infection by the Ebola virus. 802 individuals (adults and children) were included in the PostEbogui cohort. Results of follow-up show that on average one year after their initial period in hospital, ...
Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy, Nature Immunology, doi:10.1038/ni.3201, 15 juin 2015
Rosa Barreira da Silva(1,2), Melissa E Laird(1,2), Nader Yatim(1,2), Laurence Fiette(3,4), Molly A Ingersoll(1,2) & Matthew L Albert(1,2)
(1) Laboratory of Dendritic Cell Immunobiology, Institut Pasteur, Paris, France.
(2) Inserm U818, Paris, France.
(3) Human Histopathology and Animal Models, Institut Pasteur, Paris, France.
(4) Université Paris Descartes–Sorbonne Paris Cité, Paris, France.